Intellia Therapeutics, Inc. (NTLA)
14.16
-0.78
(-5.22%)
USD |
NASDAQ |
Apr 16, 16:00
14.40
+0.24
(+1.69%)
After-Hours: 04:39
Intellia Therapeutics Research and Development Expense (Quarterly) : 86.27M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Recursion Pharmaceuticals, Inc. | 83.34M |
| Personalis, Inc. | 13.07M |
| Regeneron Pharmaceuticals, Inc. | 1.481B |
| Novavax, Inc. | 73.98M |
| KalVista Pharmaceuticals, Inc. | 8.850M |